ARTICLE | Deals
Ten-figure M&A transaction with Swiss antibody company gives the pharma an immunology asset targeting IL-4RA and IL-31; builds on Proteologix deal
By Paul Bonanos, Director of Biopharma Intelligence
May 28, 2024 9:19 PM UTC
Less than two weeks after J&J acquired Proteologix for its dual-action antibody to treat immunological disorders, the pharma has reached another billion-dollar deal with Numab to give it another bispecific in the same disease area.
Johnson & Johnson (NYSE:JNJ) is paying $1.25 billion for rights to NM26, a Phase II-ready asset targeting IL-4RA and IL-31, through the acquisition of Numab Therapeutics AG subsidiary Yellow Jersey Therapeutics…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652536/j-j-adds-bispecific-for-atopic-dermatitis-via-deal-with-numab